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ABSTRACT 

An abstract of the thesis of Kimberly J. Lavoie for the Master of Science in Speech 
and Hearing Sciences presented February 12,2003. 
Title: 	 High frequency Pure Tone Audiometry and High Frequency Distortion Product 
Otoacoustic Emissions: A Correlational Analysis. 
Previous studies show that pure tone thresholds are strongly correlated with 
distortion product otoacoustic emission amplitudes when evaluating the frequency 
range from 1 to 8 kHz CAvan & Bonfils, 1993). Little is known about correlations 
between these two measures at higher frequencies from 9-16 kHz. This study 
compared pure tone thresholds and distortion product otoacoustic emissions 
(DPOAEs) in this high frequency range for 29 normal hearing subjects ages 18-30. 
Pure tone thresholds were obtained at 250-16 kHz and distortion product otoacoustic 
emissions CDPOAE) 2,211-17,675 were measured in the same ears. DPOAE 
amplitudes were measured using a constant F11F2 ratio of 1.2, with F2 values ranging 
from 2,211-17,675 Hz. Data obtained from 50 ears showed a decline in DPOAE 
amplitude with increasing frequency of the F1 and F2 primary stimulus tones. 
Behavioral thresholds demonstrated an increase with increasing frequency of the pure 
tone stimulus. Pearson r- correlation analysis demonstrated a weak relationship 
between measures. Further investigation revealed that equipment variables prevented 
accurate readings. 
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High Frequency Correlations 1 
High frequency pure tone audiometry and high frequency DPOAE's 
Current methods ofobtaining auditory thresholds include both behavioral and 
physiological measurements ofhearing sensitivity. Standard behavioral hearing tests 
include pure tone audiometry, measuring pure tone thresholds from 250-8000 Hz. 
Researchers have discovered that information about hearing sensitivity at frequencies 
beyond this standard range may provide valuable information for clinical and research 
applications (Fausti, Frey, Erickson, Rappaport, & Cleary, 1979). One application of 
high frequency audiometry is for early detection ofototoxic damage (Dreschler, Hulst, 
Tange, & Urbanus, 1989). 
A standard physiological method ofobtaining audiometric information is 
through the use ofotoacoustic emissions. Otoacoustic emissions are an indirect 
physical measurement of the outer hair cell function ofthe cochlea, and are not 
dependent on a behavioral response (Hall, 2000). There are four types of otoacoustic 
emissions: Spontaneous (SOAE), Stimulus Frequency (SFOAE), Transient (TEOAE), 
and Distortion Product otoacoustic emissions (DPOAE). Two types, transient, and 
distortion product otoacoustic emissions, are applied clinically (Hall, 2000). An 
example of the application ofotoacoustic emissions is monitoring for the ototoxic 
effects of medications (Stavroulaki, Apostopoulos, Segas, Tsakanikos, & 
Adamopoulos, 2001). 
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Several medications prescribed are known to cause auditory and vestibular 
dysfunction. Categories of ototoxic medications may include anti-inflammatory drugs, 
amino glycoside antibiotics, loop diuretics, antimalarials, chemotherapeutic agents, 
and ototopical medications (Jordan & Roland, 2000). 
The effects ofmedications are thought to be expressed throughout many areas 
of the auditory system. Areas affected may include the outer hair cells in the mid turn 
and basal turn organ ofCorti, and neurons in the spiral ganglion (Gabaizadeh et aI., 
1997). The stria vascularis may also demonstrate severe degenerative changes (Hulst, 
Dreschler, and Urbanus, 1988). At the cellular level, it is theorized that medications 
can result in an increase of intracellular calcium, thereby adversely affecting cell 
membranes, and ultimately resulting in magnesium deficiency (Cevette, Drew, Webb 
and Marion, 2000). 
Ototoxic damage to the auditory system may manifest itself clinically as an 
initial bilateral high frequency sensorineural hearing loss, which may progress to a loss 
in sensitivity at all frequencies (Jerger & Jerger, 1981). This dysfunction is most often 
identified through the application ofpure tone audiometry. 
Many studies have evaluated changes in the auditory system with pure tone 
audiometry in patients using ototoxic medications. In one such study measuring from 
250-8000 Hz for patients undergoing carboplatin chemotherapy administered in 
conjunction with osmotic opening of the blood-brain barrier, post treatment auditory 
threshold shifts were identified at 4000 and 8000 Hz (Doolittle et aI., 2001). This 
identification ofchanges in auditory thresholds supported the need for prospective 
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monitoring of frequencies higher than 8000 Hz for patients enrolled in platinum based 
chemotherapy clinical trials. 
When comparing the detectability for ototoxic damage between low frequency 
and high frequency pure tone audiometry, a 1989 study by Dreschler et aI. (1989) 
found that 34-77% of ears with ototoxic damage were discovered in an earlier stage 
when using high frequency audiometry. This study also concluded high frequency 
damage is present earlier than low frequency damage, with 12000 and 14000 Hz being 
the best test frequencies for the detection ofototoxicity (Dreschler et aI., 1989). 
Conventional and high frequency pure tone audiometry have been applied in 
case studies ofpatients receiving cisplatin chemotherapy (Fausti, Schechter, 
Rappaport, Frey & Mass, 1984). Significant changes in consecutive high frequency 
thresholds were revealed in eight of thirteen patients. When comparing low and high 
frequency audiometric configurations, it was found that the magnitude of change was 
greater in the high frequency range of 8000 Hz- 20000 Hz (Fausti et aI., 1984) 
Many studies have not only applied conventional audiometry to the evaluation 
ofpatients using ototoxic medications, but have added otoacoustic emissions to their 
regimen as well. Because the presence ofan evoked otoacoustic emission is correlated 
with normal to near normal hearing thresholds, emissions can reflect the state of the 
cochlea (Avan & Bonfils, 1993). As objective indicators of auditory function, 
emissions are not affected by extraneous influences; such as inattentiveness 
(Lonsbury-Martin, Whitehead, & Martin, 1991) therefore medically compromised 
patients can provide reliable responses despite their state ofhealth. 
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In a 1998 study of 12 children with a mean age of7.8 years, transient evoked 
otoacoustic emissions (TEOAE's) from 1000-5000 Hz were measured and compared 
to behavioral thresholds before and after a cisplatin chemotherapy regimen (Allen et 
aI., 1998). Consistent with the literature (Doolittle et aI., 2001), hearing loss of greater 
than 25 dB HL occurred in 81% ofparticipants in this study at levels higher than 4000 
Hz. When TEOAE reproducibility was compared with pure tone thresholds, it was 
found that the emission amplitudes correlated highly with pure tone audiometry 
findings. 
When comparing TEOAE's, DPOAE's and pure tone audiometry in a pediatric 
oncology population undergoing cisplatin chemotherapy (Stavroulaki et aI., 2001) it 
was found that distortion product DP grams (a method ofprofiling distortion product 
frequency analysis) are a more sensitive indicator of cochlear dysfunction than 
TEOAE's. This study further revealed statistically significant reductions in the DP 
.gram amplitudes in patient's ears with normal pure tone thresholds at 3000 Hz. The 
authors concluded that DPOAE's are more sensitive than TEOAE's and/or pure tone 
audiometry as ototoxicity screening tools. 
DPOAE's have thus been shown to be a useful objective test in screening for 
ototoxic medications, and high frequency pure tone audiometry has been shown to be 
an effective behavioral method of evaluating auditory function in ototoxicity 
monitoring. To date there have been no studies examining the correlation high 
frequency behavioral pure tone thresholds and high frequency otoacoustic emissions. 
Exploring the relationship between these two measurements in a normal hearing 
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population might prove useful for establishing baselines to measure the high frequency 
threshold changes that patients may encounter with ototoxic medications. The purpose 
of this study is to evaluate the relationship between high frequency pure tone 
audiometric thresholds, and high frequency DPOAE amplitudes. Behavioral thresholds 
will be measured at test frequencies from 250-16,000 Hz in a group of normal hearing 
persons. High frequency DPOAE's will be obtained in this same group from 1810­
17675. 
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REVIEW OF THE LITERATURE 
High Frequency pure tone audiometry 
In 1979, a system for evaluating auditory thresholds from 8000-20000 Hz was 
developed to evaluate changes in high frequency hearing sensitivity due to ototoxic 
agents and noise exposure (Fausti et aI., 1979). This system employs the use of a high 
output, low noise amplifier/filter for high fidelity, and an earphone that includes a 
ceramic diaphragm to provide a relatively flat response from 8000-20000 Hz (Fausti, 
Rappaport, Schechter, & Frey, 1982). 
This system for evaluating hearing sensitivity includes obtaining threshold 
information in the conventional frequencies from 250-8000 Hz by applying the 
standard audiometric procedure ofHughson-Westlake technique in 5 dB increments. 
Second, high frequency thresholds are then obtained from 8000-20000 Hz, using a 2 
dB bracketing tectmique (Fausti et aI., 1984). 
When recruiting participants to assess this high frequency measurement 
system, a survey evaluating frequencies above 12000 Hz found applicants to have 
highly variable hearing sensitivity on average, with medical history not accounting for 
the differences in hearing thresholds. The 21 participants from this survey 
demonstrated mean thresholds from 500-12000 Hz to be less than or equal to 20 dB 
SPL, rising slightly to 35 dB SPL at 17000 Hz, then increasing to 82 dB SPL at 20000 
Hz (Fausti et aI., 1979). 
Application of this high frequency system discovered participants to have a 
progressive sloping response from 8000-20000 Hz. Mean between test differences for 
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high frequency thresholds revealed no variations in thresholds greater than 4 dB 
(Fausti et aI., 1979). Hulst et aI. (1985) performed a similar with results consistent 
with Fausti et.aI. In evaluating 180 audiograms, standard deviation of repeated 
measurements was found to be within 4.3 dB HL from 250-20000 Hz. 
Sites of ototoxic damage 
The exact mechanisms affected by cisplatin are not known (Allen et aI., 1998) 
however; outer hair cell degeneration is a consistently reported side effect of patients 
undergoing cisplatin chemotherapy. Research evaluating the mechanisms involved in 
cisplatin ototoxicity on outer hair cells (e.g., McAlpine & Brownstone, 1990) suggests 
the ototoxic effects of cisplatin specifically disrupt the mechano-electrical transduction 
process of the outer hair cells. This causes a reduction in hair cell receptor current 
and thus subsequent hearing loss (McAlpine et aI., 1990). 
In comparing which frequencies are damaged by cisplatin ototoxicity, Mc 
Alpine et aI. (1990) discovered that "there are no differences in the susceptibility of 
high and low frequency regions of the cochlea, but that the higher frequency regions 
are more permeable to cisplatin." Studies evaluating the audiometric configuration of 
cisplatin ototoxicity demonstrate these effects in that the first area of the cochlea to 
suffer hearing loss is the high frequency region (Fausti et aI., 1984; Dreschler, Hulst, 
Tange & Urbanus, 1985). 
Other areas reportedly affected by ototoxic agents are the mid turn, and basal 
turn organ ofCorti and the spiral ganglion. In animal studies analyzing the 
otoprotective effects ofD-methionine, (Gabaizadeh et al., 1997) researchers exposed 
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the midturn, basal turn organ ofCorti and whole spiral ganglion samples of Wistar rat 
pups to cisplatin. When applying a concentration of 6 Ilg Iml ofcisplatin without an 
otoprotectant, damage to the spiral ganglion resulted in no survival of auditory 
neurons. Exposing midtum and basal turn organ of Corti samples to 4 Ilg/ml resulted 
in significantly lower hair cell densities than when compared to unexposed samples, 
and stereocilia bundle indices were reduced significantly for both outer and inner hair 
cells (Gabaizadeh et aI., 1997). 
Cisplatin and carboplatin chemotherapy agents 
Cisplatin is a potent antineoplastic agent effective against a variety of tumors 
(McAlpine et aI., 1990). Cisplatin has exhibited a broad spectrum of activity against 
epithelial cancers and has become the "foundation of curative regimens for testicular 
and ovarian cancers". It has also demonstrated significant activity against cancers of 
the head and neck, esophagus, lung, bladder, cervix, and endometrium (Go et aI., 
1999). 
Various toxic side effects have been observed after cisplatin treatment, 
including severe renal, neurologic, cytotoxic and emetogenic effects (Go et al. 1999). 
Other associated side effects may also include myelosuppression, gastrointestinal 
dysfunction, ototoxicity, and vestibulotoxicity (Hulst et aI., 1988). 
In 1981 carboplatin, an analog of cisplatin was introduced to circumvent some 
of the toxicities of cisplatin. Both are platinum complexes, but their compounds differ 
in that cisplatin contains two chloride "leaving" groups and carboplatin has a 
cyclobutane group (Go et aI., 1999). Because carboplatin and cisplatin share a similar 
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structure, they undergo the same chemical reactions and both target DNA as their 
major cytotoxic target. Concentration of the two drugs vary however, in that 
carboplatin requires 10 times higher drug concentration and longer incubation time to 
induce the same degree of change on DNA (Go et aI., 1999). 
It has been revealed that carboplatin displays less nephrotoxicity, ototoxicity, 
and neurotoxicity than cisplatin (as cited in Neuwelt et al., 1998; Go et aI., 1999) 
Renal impainnent is rare under carboplatin chemotherapy, except at extremely high 
doses (Hulst et aI., 1988) and carboplatin nausea and vomiting are less severe and 
frequent as compared to cisplatin (Go et al., 1999). 
It is believed that carboplatin and cisplatin may have different sites of damage 
to the auditory system. It has been established that carboplatin exerts toxic effects on 
inner hair cell function, whereas cisplatin's effects are exhibited on outer hair cell 
function (Hoffstetter, Ding, Powers, & Salvi, 1997). These findings may have a 
significant impact on threshold monitoring, in that DPOAE's are independent of inner 
hair cell function (Hall, 2000). DPOAE's rely on functional outer hair cells for 
auditory threshold monitoring. According to Hall (2000), clinical protocols in 
monitoring for carboplatin ototoxicity should include measures of inner hair cell 
function such as pure tone audiometry or auditory brain stem response. 
Use ofotoprotectants 
Due to the nephrotoxic, neurotoxic, myelosuppressive, and ototoxic 
mechanisms of cisplatin chemotherapy (Go et aI., 1999) researchers have evaluated the 
effects of using chemoprotectants in combination with platinum chemotherapy agents 
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in clinical and pre-clinical settings (Neuwelt et aI., 1996; Gabaizadeh et aI., 1997; 
Neuwelt et al., 1998; Campbell et ai. 1998; Doolittle et aI, 2001). A potential 
chemoprotectant against carboplatin-induced ototoxicity is delayed high dose sodium 
thiosulfate (STS). STS is effective as an otoprotectant when carboplatin is 
administered in conjunction with osmotic opening of the blood-brain barrier (Doolittle 
et aI., 2001). Agents that may provide protection against cisplatin-induced ototoxicity 
may include D-:-methionine (Campbell et. al, 1997). The mechanism ofSTS protection 
against carboplatin ototoxicity is unclear. It is currently theorized that the cochlea may 
act similar to the kidney to concentrate STS in the perilymph or endolymph. High 
concentrations ofSTS may act to inactivate carboplatin at the site of cochlear damage 
(Neuwelt et al. 1996). This inactivation is thought to occur through the chemical 
reaction of the thiol binding to the electrophile platinum, thus rendering the platinum 
inactive (Neuwelt et aI., 1998, Doolittle et al, 2001). 
Animal studies evaluating carboplatin ototoxicity in a guinea pig model 
demonstrated protection when STS was given up to eight hours subsequent to 
carboplatin (Neuwelt et al., 1996). Determination of the effect ofSTS on carboplatin 
induced ototoxicity was by electrophysiological measurements and cochlear hair cell 
count (Neuwelt et al., 1996). 
Studies evaluating the efficacy of high dose STS in patients with malignant 
brain tumors, noted what appeared to be a preservation ofhearing (Neuwelt et aI., 
1998). In Neuwelt et al. 's study (1998), twenty nine patients ranging from 2-63 years 
of age treated with carboplatin followed by one dose of STS, were compared to a 
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historical group of 19 patients treated with carboplatin that did not receive STS. 
Patients with excellent baseline hearing (thresholds < 20 dB HL in the frequency range 
of 250-8000 Hz) showed little change in high frequency thresholds with a mean loss of 
8 ± 5.6 dB after the first carboplatin followed by STS treatment. In comparison, 
patients in the (no STS) historical group with excellent baseline hearing thresholds, 
demonstrated a mean hearing loss of30.0 ± 8.4 dB after the first carboplatin treatment 
(Neuwelt et aI., 1998). 
This 1998 study further demonstrated that 50% of patients with impaired 
baseline hearing (thresholds> 20 dB HL in the frequency range of250-8000 Hz) 
developed an additional 20 dB threshold shift, despite treatment with one dose of STS 
(Neuwelt et al. 1998). Because of this finding, the treatment regimen was altered. 
Patients with impaired baseline hearing thereafter received a second dose of STS, 6 
hours following carboplatin treatment (Doolittle et aI., 2001). 
In a more recent study, audiologic data from patients who received STS two (or 
two and six) hours after carboplatin, and patients who received STS four (or four and 
eight) hours after carboplatin, were compared with the historical (no STS) group. 
Spearman rank correlation coefficients showed decreased rates ofototoxicity, with 
greater decay in STS (Doolittle et aI., 2001). 
Otoacoustic Emissions 
Otoacoustic emissions (OAE's) are the result ofbiomechanical activity 
associated with normally functioning outer hair cells. This motility produces a signal 
within the cochlea that is transmitted through the middle ear and ossicles. The signal is 
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then measured with a microphone inserted into the ear canal (Gelfand, 1997). Because 
OAEs can reflect the state of the cochlea, they are applied clinically to provide an 
objective measure of auditory sensitivity (Hall, 2000). There are two general 
categories of otoacoustic emissions, spontaneous and evoked. 
Spontaneous otoacoustic emissions (SOAEs) are emissions that occur in the 
absence of external stimuli. They consist of energies at one or more frequencies 
emitted by the normal ear (Hall, 2000). SOAEs are most commonly detected in the 
1000-2000 Hz region where reverse transmission through the middle ear is most 
efficient (Kemp, 1986). Clinical application ofSOAEs are limited, as they can be 
detected in only 50% of ears with normal hearing, with a genetic preference for 
females, they have variable amplitudes over time, and frequencies at which they occur 
are limited (Lonsbury-Martin et aI., 1991). 
Evoked otoacoustic emissions are emissions that occur in response to 
presentation of an acoustic stimulus. These emissions can be further categorized into 
three subtypes according to the stimuli used to elicit them. Transient evoked emissions 
(TEOAEs) are elicited by a click, or toneburst; stimulus frequency (SFOAEs) are 
evoked by a single continuous pure tone; and acoustic distortion products (DPOAEs) 
are generated in response to two continuous pure tones separated using a prescribed 
frequency difference (Lonsbury-Martin et aI., 1991). 
SFOAEs are emissions that are evoked using a constant pure tone stimulus 
presented at a low intensity level swept or changed slowly across a region of 
frequencies (Hall, 2000). SFOAEs are more difficult to analyze than other types of 
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emissions, because it is necessary to separate the SFOAE from the stimulus tone that is 
simultaneously present in the ear canal, and is larger than the emission (Lonsbury­
Martin et.al. 1991). There are currently no available devices for recording SFOAEs; 
therefore they are the least studied experimentally, and clinically (Hall, 2000). 
TEOAEs are acoustical signals emitted by outer hair cells of the cochlea on 
presentation of transient stimuli, such as clicks, or tone bursts (Ferguson, Smith, 
Davis, & Lutman, 2000). TEOAE's are a waveform that is generated in the cochlea, 
and detected in the ear canal several milliseconds following presentation of a stimulus 
(Gelfand, 1997). The average latency, or time between waveforms is typically 5-20 
milliseconds; time averages tend to decrease with increase in OAE frequency. Spectral 
analysis of these waveforms can provide frequency specific information across the 
frequency region from 0-5000 Hz (Gelfand, 1997). 
Click evoked emissions, such as TEOAE's are thought to reflect the presence 
ofouter hair cell function of the cochlea. When sensitivity tuning of the inner ear is 
impaired within a certain frequency range, spectral components of the TEOAE within 
that same frequency range are expected to be altered (Avan, Elbez, & Bonfils, 1997). 
This phenomenon supports the clinical utility of TEOAEs in monitoring the state of 
the cochlea in areas such as newborn infant hearing screening and ototoxicity 
monitoring (Allen et al, 1998). 
DPOAEs are emissions that are elicited by the simultaneous presentation of 
two pure tones, called primaries, closely spaced in frequency. The two primaries 
activate the cochlea in the same region of the basilar membrane, but due to nonlinear 
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properties of a healthy cochlea, a third combination tone is generated in the frequency 
region where the two primary frequencies overlap. This is combination tone called an 
acoustic distortion product (Hall, 2000). 
The strongest DPOAE in human ears occurs at the cubic difference frequency, 
2f1-f2, in which f1 represents the lower frequency stimulus, and f2 represents the 
higher frequency primary (Lonsbury-Martin et aI., 1991). DPOAE amplitudes may 
vary with the level of the primary tones, as an increase in level of the primaries results 
in an increase emission size (Gelfand, 1997). 
Research supports that DPOAE amplitudes provide information as to the 
frequency specificity of the cochlea (Avan et aI, 1993; Moulin, Bera & Collet, 1994). 
When analyzing DPOAE amplitudes elicited by low frequency primaries, researchers 
have found significant correlations with auditory thresholds at the mean frequencies of 
the primary tones. 
DPOAEs can be measured using two methods; a DPOAE audiogram, which 
shows DPOAE amplitude as a function of the geometric mean (generation site) of the 
two frequencies, or an input/output function, which measures DPOAE amplitude as a 
function of stimulus level at a given frequency (Lonsbury-Martin, et aI, 1991). 
Because of their high sensitivity, reliability, an~ objectivity, DPOAEs are used 
routinely as a measure ofhearing sensitivity not only for patients using ototoxic 
medications, but for patients unable to perform behavioral testing, newborn and infant 
testing, testing persons with multiple disabilities, and malingerers (Stavroulaki et aI, 
2001). 
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METHODS 
Participants 
Twenty nine students from Portland State University volunteered to participate 
in this study. To be eligible for inclusion, participants were between 18-30 years of 
age at the time of enrollment in this study. Participants had normal hearing sensitivity 
at audiometric test frequencies from 250-8000 Hz. Criteria for exclusion from this 
study included hearing thresholds above 20 dB HL from 250-8000 Hz, the absence of 
otoacoustic emissions from 2000-16000 Hz, or history of significant ear disease or 
significant noise exposure. 
Volunteers were recruited by flyers posted in hallways at Portland State 
University, and by announcement in Speech and Hearing science classrooms. 
Volunteers were instructed to register for participation bye-mail or phone. 
MaterialslInstrumentation 
Testing was performed at the Children's Developmental Rehabilitation Center 
(CDRC) at Doernbecher Children's Hospital. Following a brief otoscopic evaluation, 
tympanometry was performed using a Orason-Stadler OSI 33 middle ear acoustic 
analyzer. Middle ear assessment was made using a Orason-Stadler OSI single use 
silicon probe tip, with a 226 Hz probe tone. Following tympanometry, DPOAE's were 
measured in a double walled acoustic chamber at CDRC to ensure an adequately low 
noise floor. An Etymotic Research (ER 2) transducer was used to obtain DPOAE's. 
An Intelligent Hearing Systems Smart OAE program was used to acquire emissions 
from 1810-17675 Hz. 
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A daily biological calibration of the audiometer was performed to ensure 
adequate output before testing began. An exhaustive calibration was performed on the 
audiometer prior to the initiation of the study_ DPOAE calibration in a 1 cc coupler 
was performed to confmn adequate transducer linearity prior to data collection. No 
significant 2F 1-F2 components at any of the primary frequency combinations. The 
DPOAE microphone was calibrated using a within the ear approach measurements on 
each individual prior to obtaining measurements, according to the manufacturers 
recommendations. 
L2 and L1levels were set to 65 dB and 55 dB SPL. The F11F2 ratio was set at 
the default setting of 1.2 (Hall, 2001). 
Table 1. F1 and F2 primary stimulus tones 
Frequency combination 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Fl,Hz F2,Hz 
1810 2211 
2152 2631 
2563 3120 
3042 3717 
3619 4421 
4304 5253 
5125 6250 
6094 7434 
7238 8832 
8617 10505 
High Frequency Correlations 17 
(Table 1 continued) 
11 10241 12500 
12 12178 14858 
13 14486 17675 
All audiometric testing was conducted within an Acoustic Systems double 
walled acoustic chamber. Pure tone thresholds were obtained using an Interacoustics 
AC 40 clinical· audiometer. Thresholds were obtained from 250 through 8000 Hz 
under TDH 39P headphones. High frequency thresholds from 9000-20000 Hz were 
obtained using Sennheiser HDA 200 headphones. Using a technique introduced by 
Fausti et al. (1984), standard audiologic techniques were employed to obtain 
thresholds from 250-8000 Hz, and a modified Hughson-Westlake technique in 2 dB 
increments were used to obtain pure tone thresholds from 8000- 20000 Hz. 
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RESULTS 
High frequency DPOAEs and pure tone thresholds were collected from 29 
participants. This yielded information on these two types of measurements from a 
total of 50 ears. 
Examples ofDPOAE amplitudes recorded from one subject are given in figure 
1A. Each plot shows amplitude of sound recorded in the ear canal as a function of 
frequency. Two tones were presented to this subject's ears. The Fl primary was 
presented at 1810Hz, stimulating at a level of 65 dB SPL. The F2 primary was 
presented at 2211 Hz. The amplitude of the F2 stimulus was 55 dB SPL. These two 
tones resulted in a distortion product at a frequency of2F1-F2, which in this case was 
1409 Hz. The measured amplitude was 16 dB SPL 
Figure 1 B is a graph of an acoustic distortion product generated with higher 
frequency primaries on the same subject. The Fl primary was presented at 5125 Hz at 
a level of 65 dB SPL. The F2 stimulus was presented at 6250 Hz. The F2 intensity 
was 55 dB SPL. When using 5125 and 6250 as the two primaries, this resulted in a 
2FI-F2 frequency of4001 Hz. The amplitude of the DPOAE was 8 dB SPL. As the 
stimulus frequency increases above 2000 Hz, the distortion product amplitudes are 
expected to reduce (Hall, 2000). The difference between the amplitude of the DPOAE 
between figures 1 and 2 was 8 dB. 
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Figure 1 C is a graph of an acoustic distortion product at the high frequency 
region (base) of the basilar membrane. The Fl primary was presented at 12178 Hz. 
The amplitude was 65 dB SPL. The F2 primary was presented at 14858 Hz, with an 
intensity level of 55 dB SPL. When using 12178 and 14858 as the two primaries, this 
resulted in a 2FI-Fl frequency of 9498 Hz, with an amplitude of2 dB SPL. 
Figure 2 gives 2FI-F2 distortion product amplitude as a function ofF2 
frequency for one subject. Thirteen DPOAE combinations were measured with F2 
frequencies from 2211 to 17675 Hz. The frequency ratio ofF2 to Fl for each of the 
primaries was 1.22. This plot shows all DP emissions measured for all primaries 
presented to each ear. The shaded area on the graph represents the noise floor during 
testing. This measure varied with each subject, but in this case was below -10 dB 
SPL. As demonstrated in figure 2, distortion product amplitude tend to decrease with 
increasing frequency. 
In Figure 3 distortion product amplitude is plotted as a function ofF2 
Frequency for all subjects. As with the individual data in Fig. 2, the group data in Fig. 
3 tend to show a decline in DP level with increasing frequency. The mean amplitude 
from 2211-3717 Hz was 5.7 dB SPL, the mean amplitude from 4421-8832 Hz was 1.4 
dB SPL, and the mean amplitude from 10505-17675 Hz was -1 dB SPL. The 
amplitude range throughout the frequency spectrum from 2211 to 17675 Hz was an 
average of27 dB SPL from 2211-3717 Hz, an average range of27 dB SPL from 4421­
8832 Hz, and an average range of32 dB SPL from 10505-17675 Hz. Thus amplitude 
variability appears to be similar across frequencies. 
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Behavioral thresholds are given in Figure 4 where pure tone thresholds are 
plotted as a function of frequency for all subjects. The most notable effect here is the 
increase in pure tone thresholds with increasing frequency. Mean thresholds from 
250-3000 Hz were 7 dB HL. Mean thresholds from 4000-9000 Hz were 18 dB HL, 
and 32 dB HL from 10000-16000 Hz. A range of 17 dB was found in thresholds from 
250-3000 Hz, a 37 dB range from 4000-9000 Hz, and a 70 dB range was illustrated 
from 10000 to 16000 Hz. Thus thresholds have the greatest variability in the high 
frequencies. 
The relationship between behavioral thresholds and DPOAE amplitude 
between subjects was explored by conducting a Pearson r correlation analysis at each 
frequency. The results of this analysis are given in Table 2. A negative relationship 
between variables was found in 10 of the 14 bivariate correlations. The Pearson r­
values had a range of -.032 to -.46. The remaining 4 correlations had a positive value, 
with a range of .06 to .18 indicating a weak positive correlation for these measures. 
Two of the bivariate correlations, 12000 and 14000 Hz were found to be 
significant at the .05 level. One frequency, 4000 Hz, was found to be significant at the 
.01 level, with an r-value = -.461, indicating a moderate negative correlation. 
Table 2 displays the analysis of bivariate correlations for each frequency, 
including the Pearson-r correlation value and significance: 
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Table 2. Pearson r correlation analysis 
Frequency 
PT 2000 

DP 2361 

PT 3000 

DP 3171 

PT 4000 

DP 4421 

PT 6000 

DP 6250 

PT 8000 

DP 8832 

PT 9000 

DP 10505 

PT 10000 

DP 10505 

PT 11200 

DP 10505 

PT 12500 

DP 12500 

PT 14000 

DP14858 

PT 16000 

DP 14858 

PT 16000 

DP17675 

Pearson r 
-.18 
-.099 
-.461 
-.195 
-.118 
.183 
.067 
-.035 
-.302 
-.358 
-.282 
.086 
Significance (2-tailed) 
.217 

.499 

.001 

.180 

.420 

.208 

.646 

.812 

.035 

.012 

.049 

.558 
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The scatter plots in figure 5A, 5B, and 5C illustrate the relationship between 
the objective and sUbjective measurements of hearing sensitivity for all subjects at the 
three frequencies with high correlation. If the variables are correlated as suspected, a 
diffuse clustering ofdata points spread around a downward sloping pattern is 
expected. 
Figure 5A is a scatter plot that displays 4000 Hz pure tone thresholds as a 
function of 4421 Hz DPOAE amplitudes. Each data point on the graph represents a 
subject response. Figure 5B is a scatter plot that displays the relationships of the 
12500 Hz pure tone thresholds and 12500 Hz DPOAE amplitudes in all SUbjects. 
Figure 5C is a scatter plot that displays 14858 DPOAE amplitudes and 14000 Hz pure 
tone thresholds in all subjects. The correlations between the two measures therefore 
appear to be weak. 
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amplitude for an F2 frequency of 4,000 Hz across subjects. A dispersed pattern of 
data points is revealed. 
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DISCUSSION 
The aim of this study was to evaluate relationship between High frequency 
pure tone thresholds and High frequency DPOAE's. Data obtained from 50 ears 
showed a decline in DPOAE amplitude with increasing frequencies of the primaries. 
This trend is consistent with the findings, as stimulus frequency increases above 2000 
Hz, a progressive reduction ofDP amplitude for higher frequency stimuli were 
recorded when the fl/f2 ratio is kept at 1.22 (Hall, 2000). The present study indicates 
that the decline continues to F2 values as high as 17,675 Hz. Our data also 
demonstrated an increase in behavioral thresholds with increasing frequency. This is 
consistent with the findings ofFausti et aI., 1979, who showed that thresholds for 
normal hearing individuals increase with test tone frequencies from 8000-20000 Hz. 
The literature has established significant correlations between DPOAEs and 
pure tone audiometry when evaluating the frequency range from 250-8000 Hz (A van 
et.al, 1993; Moulin, Bera & Collet, 1994). Our data show a relatively poor correlation 
between the two types of measures within this range of frequencies and for frequencies 
above 8000 Hz. Possible reasons for the discrepancy in our findings are discussed 
below. 
An inherent problem with behavioral pure tone thresholds, is the fact that they 
are a subjective measurement at risk to variability. When performing a Pearson r 
correlation analysis between repeated measures, all thresholds were found to have a 
high statistical significance, with an r-value ofat least .905 for all frequencies tested 
from 9000 through 16000 Hz. This indicates a high level of reproducibility between 
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repeated measures. The range of high frequency thresholds was found to be within the 
clinically acceptable range of± 10 dB SPL for repeated thresholds (Frank et.al., 1991). 
It is therefore unlikely that the low correlation was due to poor reliability ofour 
behavioral thresholds. 
Repeated measures were not performed on OAEs because they are generally 
not subject to patient variability, so an evaluation ofequipment was performed. The 
Intelligent Hearing Systems (IHS) is the only commercially available device capable of 
measuring high frequency DPOAEs for a clinical setting. There are currently no ANSI 
standards for high frequency measurements, so protocols and calibrations were 
performed using the manufacturer's recommendations with the software and probe tips 
recommended by IHS. 
As outlined in the methods section, measurement of the transducer output 
using a 1 cc coupler was performed prior to data collection to evaluate sthnulus purity. 
Emissions should not exist in a hard walled cavity if the transduction system is linear. 
We found that there were no significant distortion products that were generated by the 
transducer, so we therefore assumed that the system was linear. However, when a 
similar check was made following data collection, significant DPOAE amplitudes 
were recorded across the frequency spectrum from 2211 to 17675 Hz, with amplitudes 
ranging from -13 to 10 dB SPL. This suggests that at some point during data 
collection the system may have become nonlinear. 
Two possible explanations of this are standing waves and electrical 
interference. Standing waves are cancellations and reinforcements of sound waves due 
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to reflections or interactions between the stimulus and tympanic membrane (Siegel, 
1994). Standing waves can be averaged into amplitude measurements, causing the 
response to be underestimated or overestimated in interpretation. 
Even when a transducer is designed for optimal conditions, a strong input 
signal can drive a transducer to saturation. When saturation occurs, there will be 
distortion of the output waveform, so that it will not have the same shape as the input 
waveform (Gibilisco, 1993). However, our transducer output was only 65 dB SPL, 
while the standard output values are acceptable up to 75 dB SPL without driving the 
transducer into saturation. Therefore, transducer saturation was most likely not a 
factor. 
Due to the fact that there was change in transducer output calibration measures 
between initiation and completion of the study, this most likely compromised our data 
accuracy. Since our Intelligent Hearing Systems equipment was producing artifacts, 
caution should be used that emissions measured are actual measurements and are not 
artifacts. 
High frequency OAE equipment should come equipped with a fool proof 
method of calibration. It is recommended that future protocols include a daily coupler 
calibration in addition to an in-the-ear calibration measure before acquiring data on 
each subj ect. 
High frequency DPOAE's and high frequency pure tone audiometry should be 
used in future studies to evaluate correlational relationships for use in ototoxicity 
monitoring with different age groups. With properly functioning equipment, this 
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research will provide valuable information to the medical and research communities. 
Other investigations could include a correlational analysis on a hearing impaired 
population, without adjusting protocols performed in our study. DPOAEs would not 
be present with hearing thresholds poorer than 35 dB HL. Significant DPOAE 
amplitudes on this population would provide evidence as to the presence of standing 
waves or electrical interference. 
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